Teacher Retirement System of Texas Acquires 3,942 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Teacher Retirement System of Texas increased its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 44.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,860 shares of the company’s stock after acquiring an additional 3,942 shares during the period. Teacher Retirement System of Texas’ holdings in Vera Therapeutics were worth $544,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. AlphaQuest LLC purchased a new stake in shares of Vera Therapeutics during the fourth quarter valued at approximately $34,000. E Fund Management Co. Ltd. grew its holdings in Vera Therapeutics by 22.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock worth $262,000 after acquiring an additional 1,130 shares during the last quarter. KBC Group NV grew its holdings in Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after acquiring an additional 1,387 shares during the last quarter. Arizona State Retirement System increased its position in shares of Vera Therapeutics by 22.9% in the fourth quarter. Arizona State Retirement System now owns 12,586 shares of the company’s stock valued at $532,000 after acquiring an additional 2,348 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Vera Therapeutics by 27.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company’s stock valued at $568,000 after acquiring an additional 2,882 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on VERA shares. The Goldman Sachs Group started coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $58.00 target price on the stock. Wolfe Research initiated coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price objective on the stock. Guggenheim upped their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Finally, JPMorgan Chase & Co. cut their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $64.67.

Insiders Place Their Bets

In other news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total value of $730,450.00. Following the sale, the chief executive officer now directly owns 143,603 shares of the company’s stock, valued at $5,993,989.22. The trade was a 10.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 21.70% of the company’s stock.

Vera Therapeutics Price Performance

Shares of VERA stock opened at $24.02 on Tuesday. The business’s fifty day moving average is $30.74 and its 200 day moving average is $38.80. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -9.20 and a beta of 1.17. Vera Therapeutics, Inc. has a twelve month low of $22.34 and a twelve month high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. Research analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.